the web site mentions anti-inflammatory theory, and mentions this existing pharmaceutical: canakinumab
But its not clear if he is using that substance.
Those treated in CANTOS (trials) had a 15% reduction in deaths from heart attacks, stroke and cardiovascular disease combined. However, there were serious side-effects, and no statistically significant overall survival benefit. Nonetheless, David Goff, director of the division of cardiovascular sciences at the National Heart, Lung and Blood Institute feels the "public health impact potential is really substantial,” and estimates that in the United States 3 million people might benefit from canakinumab.